Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics is showing strong potential for success in autoimmune diseases, particularly with its lead candidate KYV-101, which has shown positive results in a Phase 1 trial for stiff-person syndrome (SPS). The company has received FDA alignment for its regulatory filings and is on track to submit a BLA in 1H26, with a potential commercial launch in 2027. The company's financials show controlled spending and a solid cash runway, mitigating dilution risks. However, there are still risks associated with the durability of responses and potential failures in other indications. Overall, the company's strong clinical data and promising outlook make it a positive investment opportunity.

Bears say

Kyverna Therapeutics is facing a challenging market for its product, KYV-101, as the RA field already has many chronic treatment options available. The limited data from the Phase 1 dataset and the need to show a significant and durable advantage compared to existing treatments in terms of efficacy, safety, logistics, and cost, make it difficult for investors to justify the company's position in the market. Even though there is potential for incremental upside with their EULAR update for RA, the main focus and valuation for the company lies in the execution of their product for skin-predominant SPS and gMG.

KYTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 4 analysts, KYTX has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.